Elinzanetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with the menopause

Elinzanetant is in clinical development for the treatment of vasomotor symptoms (hot flashes) in women undergoing the menopause. The menopause occurs between 45 and 55 years of age and is caused by declining hormone levels. The declining hormone levels mean that neurons (nerve cells) in the hypothalamus (small part in the brain) become hyperactive and disrupt body heat control mechanisms, resulting in hot flashes. The symptoms of these are a sudden feeling of warmth, a rapid heartbeat and perspiration. Over one-third of women report severe symptoms, which can last 10 years or more after the last menstrual period. Vasomotor symptoms may have a negative impact on sleep, mood and quality of life. Current treatments include hormone replacement therapy, but this is not suitable for all women because of medical contraindications, personal preference or an increased risk of disease including some cancers. Therefore, there is a need for effective nonhormonal therapy for menopause-related vasomotor symptoms.